Changchun Baike Biotechnology Co., Ltd

Short Form Report on Changes in Equity

Name of listed company: Changchun Baike Biotechnology Co., Ltd

Stock abbreviation: Baike Biotechnology

Stock Code: 688276

Stock listing location: Shanghai Stock Exchange

Information disclosure obligor: Wei Xuening

Residence: Changning District, Shanghai***

Mailing address: Changning District, Shanghai***

Nature of change in shares: Reduction of shareholding (shareholding ratio reduced to 5%)

Date of signing: November 6, 2024

Disclosure Obligor Statement

1. This report is prepared by the information disclosure obligor in accordance with the Securities Law of the People's Republic of China, the Administrative Measures for the Acquisition of Listed Companies, the Standards for the Content and Format of Information Disclosure of Companies Offering Securities to the Public No. 15 - Report on Changes in Equity and relevant laws, regulations and normative documents.

2. The Disclosure Obligor has obtained the necessary authorization and approval to sign this report, and its performance does not violate or conflict with any provision in the Articles of Association or internal rules of the Disclosure Obligor.

3. In accordance with the provisions of the Securities Law of the People's Republic of China, the Administrative Measures for the Acquisition of Listed Companies, and the Standards for the Content and Format of Information Disclosure of Companies Offering Securities to the Public No. 15 - Report on Changes in Equity, this report has fully disclosed the changes in the shares in which the information disclosure obligor has an interest in Changchun Baike Biotechnology Co., Ltd.

4. As of the date of signing this report, except for the shareholding information disclosed in this report, the information disclosure obligor has not increased or decreased its shares in Changchun Baike Biotechnology Co., Ltd. by any other means.

5. The change in equity is based on the information contained in this report. The information disclosure obligor has not entrusted or authorized any unit or individual to provide information not listed in this report and to make any explanation or explanation of this report.

6. The information disclosure obligor undertakes that there are no false records, misleading statements or material omissions in this report, and assumes individual and joint legal liability for its authenticity, accuracy and completeness.

Table of Contents

Section 1: Interpretation ...... 4

Section 2: Introduction to Information Disclosure Obligors ...... 5

Section 3 Purpose of Equity Change and Share Ownership Plan ...... 6

Section 4 Methods of Changes in Equity ...... 7

Section 5 Trading of Shares of Listed Companies in the Preceding 6 Months ...... 9

Section 6 Other Major Matters ...... 10

Section 7 Documents for Reference ...... 11

Section 8: Statement of Information Disclosure Obligor...... 12

Schedule: Short Form Report on Changes in Equity ...... 13

Section 1: Interpretation

In this report, unless otherwise indicated, the following abbreviations shall have the following specific meanings:

Abbreviated as paraphrasing

Listed Company/Company/Baikesheng refers to Changchun Baike Biotechnology Co., Ltd

thing

Information Disclosure Obligor means Wei Xuening

Report/This Report refers to the short-form report on changes in equity of Changchun Baike Biotechnology Co., Ltd

book

The change in equity refers to the equity of the information disclosure obligor to hold 5% of the shareholding after the reduction

Change Behavior

China Securities Regulatory Commission means the China Securities Regulatory Commission

SSE / Stock Exchange means the Shanghai Stock Exchange

Note: Unless otherwise specified, all values in this report are kept to 4 decimal places, and if the sum of the sub-values does not match the mantissa of the total, it is due to rounding in the calculation of the data.

Section 2: Introduction of Information Disclosure Obligors

1. Basic information of the information disclosure obligor

Name: Wei Xuening

Gender: Male

Nationality: Chinese

IC Number: 110108************

Residence and mailing address: Changning District, Shanghai***

Residency in another country or region: No

2. The information disclosure obligor holds or controls more than 5% of the outstanding shares of other listed companies at home and abroad

As of the date of signing this report, the information disclosure obligor does not have an interest in other listed companies at home or abroad with shares that reach or exceed 5% of the issued shares of the company.

Section 3 Purpose of Equity Change and Shareholding Plan

1. The purpose of this change in equity

This change in equity is due to the reduction of the company's shares by the information disclosure obligor due to its own capital needs, resulting in the proportion of shares owned by the information disclosure obligor to 5%.

2. The plan of the information disclosure obligor to increase or reduce its holdings of the listed company's shares in the next 12 months

In addition to the centralized bidding plan to reduce shareholdings, the information disclosure obligor has not yet had a clear plan to increase or reduce its shareholding in the company in the next 12 months, and it is not excluded that it will continue to reduce its shareholding in the company within 12 months after the completion of this equity change. If there is a plan or there is a change in relevant rights and interests, the information disclosure obligor will perform the information disclosure obligation in a timely manner in strict accordance with the provisions of relevant laws and regulations.

Section 4: Methods of Changes in Equity and Interests

1. The shares of the listed company held by the information disclosure obligor before the change in equity

Before this change in equity, Wei Xuening, the information disclosure obligor, held 36,010,000 shares of the company, with a shareholding ratio of 8.7225%.

2. The basic situation of this change in rights and interests

During the period of this equity change, Mr. Wei Xuening, the information disclosure obligor, reduced his holdings of the company's shares through centralized bidding and block trading as follows:

Shareholders Reduction method Reduction time Reduction of holdings Reduction of holdings Reduction of holdings Reduction of quantity Change ratio

Name Copy Type (Shares) (%)

Centralized auction 2022/7/28 RMB 2,000,000 0.4844

~9/7/2022 Common Stock

Centralized auction transaction 2022/11/22 RMB 3,000,000 0.7267

Wei Xuening ~5/5/2023 Common stock

Block Trade 2022/8/17~ RMB 10,055,312 2.4356

6/5/2023 Common stock

Centralized auction transaction 2024/11/5~ RMB 271,808 0.0657

11/6/2024 Common stock

Total 15,327,120 3.7225

The shareholding before and after this equity change is as follows:

Shareholders Shares held before this change Shares held after this change

Name Nature of shares Ratio of total share capital to total share capital

Number of shares Example (%) Number of shares Proportion (%)

Wei Xue Total shares 36,010,000 8.7225% 20,682,880 5.0000%

Ning Where: Unlimited

Conditional outstanding shares 36,010,000 8.7225% 20,682,880 5.0000%

3. Restrictions on the rights of the information disclosure obligor to have equity shares in the listed company

As of the date of this report, the information disclosure obligor holds 20,682,880 shares of the company, accounting for 5.0000% of the company's total share capital

1,166,680 shares, the details of which are detailed in the company's publication on the Shanghai Stock Exchange website on October 9, 2024

"Announcement of Changchun Baike Biotechnology Co., Ltd. on the Judicial Freezing of Part of the Shares of Shareholders Holding More than 5% of the Shares" (Announcement No.: 2024-034) of the station (www.sse.com.cn). Except for the above-mentioned frozen shares, the remaining shares do not have any rights restriction or transfer restriction such as pledge, seizure or freezing.

Section 5 Trading of shares of listed companies in the previous 6 months

In addition to the changes in equity disclosed in this report, the information disclosure obligor has not bought or sold the company's shares in the six months prior to the date of this change in equity.

Section 6: Other major matters

As of the date of signing this report, the information disclosure obligor has truthfully disclosed the relevant information of the change in equity in accordance with the relevant regulations, and there is no other material information that the information disclosure obligor should disclose but has not disclosed in accordance with the law and relevant regulations.

Section 7: Documents for reference

1. Documents for reference

1. A copy of the ID card of the person obligated to disclose information;

2. This report signed by the information disclosure obligor;

3. Other documents required by the China Securities Regulatory Commission or the Shanghai Stock Exchange for reference.

2. Locations for reference

This report and the above-mentioned documents are available for inspection by investors at the office of the board of directors of the listed company.

Section 8: Statement of the Disclosure Obligor

I undertake that there are no false records, misleading statements or material omissions in this report, and I assume individual and joint legal responsibility for its authenticity, accuracy and completeness.

Information Disclosure Obligor (Signed): Wei Xuening

Signed: November 6, 2024

Schedule I

Short Form Report on Changes in Equity

Basic information

Name of listed company: Changchun Baike Biotechnology Co., Ltd. Location of listed company: Chaoyang District, Changchun City, Jilin Province

138 Excellence Street

Stock abbreviation: Baike Biotech Stock code: 688276

Information Disclosure Obligor Wei Xuening Information Disclosure Obligor Changning District, Shanghai***

Name Residence

Shares with an interest Increase □ decrease? Whether there are concerted actors There are □

Change in number No change, but change in shareholder□ None?

The information disclosure obligor is □ the information disclosure obligor is the □

Is it a listed company No? Is it a listed company No?

The largest shareholder and the actual controller

Centralized trading through the stock exchange? Agreement to transfer □

Methods of change of equity Administrative transfer or change of state-owned shares□ Indirect transfer □

(Multiple selections) Obtain new shares issued by listed companies□ □ execution court ruling

Inheritance□ Gift □

Other? Block trades

Information Disclosure Obligor

Equity before disclosure Stock type: RMB ordinary shares, A shares

Number of shares and number of shares: 36,010,000 shares

Listed company issued shareholding ratio: 8.7225%

Proportion of shares

Changes in the rights and interests Stock type: RMB ordinary shares A shares

After that, the number of changes in information disclosure: 15,327,120 shares

Percentage of change in employee's equity: 3.7225%

Number of shares and changes Number of shares held after change: 20,682,880 shares

Ratio Shareholding after change: 5.0000%

Time in listed companies: July 28, 2022 ~ November 6, 2024

Equity share changes: centralized auction trading, block trading

When and how it moved

Has it been adequately disclosed Yes□ No□ Not applicable?

Source

Information Disclosure Obligor

Is it intended for the next 12 Yes□ No?

Continued to increase holdings during the month

Information Disclosure Obligor

In the previous 6 months Yes □ No?

Buy and sell on the secondary market

The shares of the listed company

(There is no text on this page, it is the signature page of the "Report on Changes in Equity of Changchun Baike Biotechnology Co., Ltd.")

Information disclosure obligor: Wei Xuening

Date: November 6, 2024